Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
TransCode Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
RNAZ
Nasdaq
2830
www.transcodetherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
- Feb 6th, 2025 1:00 pm
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
- Feb 4th, 2025 9:15 pm
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
- Jan 14th, 2025 1:00 pm
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
- Jan 7th, 2025 1:00 pm
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
- Dec 18th, 2024 1:00 pm
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
- Nov 29th, 2024 9:25 pm
Transcode Therapeutics issues 21.2M shares at 37.7c in private placement
- Nov 28th, 2024 12:20 pm
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
- Nov 27th, 2024 12:00 pm
Transcode Therapeutics announces 1-for-33 reverse stock split
- Nov 26th, 2024 12:05 pm
TransCode Therapeutics Open Letter to Shareholders
- Nov 12th, 2024 12:00 pm
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
- Nov 5th, 2024 12:00 pm
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
- Oct 23rd, 2024 11:00 am
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
- Oct 10th, 2024 11:00 am
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
- Sep 17th, 2024 11:00 am
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
- Sep 10th, 2024 11:00 am
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
- Sep 5th, 2024 11:00 am
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
- Aug 15th, 2024 11:00 am
TransCode Therapeutics, Inc. Announces Closing of Public Offering
- Jul 24th, 2024 8:05 pm
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
- Jul 23rd, 2024 2:30 am
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
- Jul 22nd, 2024 8:07 pm
Scroll